Walleye Capital
FATE icon

Walleye Capital’s Fate Therapeutics FATE Stock Holding History

Walleye Capital’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,600
Closed -$31.9K – 4484
2023
Q1 		$31.9K Sell
5,600
-3,900
-41% -$23.5K ﹤0.01% 3296
2022
Q4 		$95.9K Buy
9,500
+6,000
+171% +$113K ﹤0.01% 2373
2022
Q3 		$78K Buy
+3,500
New +$101K ﹤0.01% 2504

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Walleye Capital's FATE Position: Q2 2025 in Review

Walleye Capital sold out of Fate Therapeutics (FATE) in Q2 2025, closing a stake of 72,286 shares — an estimated $57.1K sold.

Walleye Capital first reported a position in FATE in Q4 2020 and held it in 12 quarters. The position peaked at $1.85M in Q2 2023. 139 funds tracked by Wall St. Rank hold FATE as of Q2 2025.

  • Walleye Capital reported no remaining Fate Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Walleye Capital sold 72,286 Fate Therapeutics shares in Q2 2025, an estimated $57.1K.
  • Walleye Capital first reported a position in Fate Therapeutics in Q4 2020 and held it in 12 quarters.
  • Walleye Capital's Fate Therapeutics position peaked at $1.85M in Q2 2023.
  • 139 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2025.

Based on Walleye Capital's 13F filing for Q2 2025, filed 13 Aug 2025.